- Report
- May 2025
- 182 Pages
Global
From €5338EUR$5,850USD£4,536GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2738EUR$3,000USD£2,326GBP
- Report
- June 2020
- 753 Pages
Global
From €3011EUR$3,300USD£2,559GBP
- Report
- September 2021
- 102 Pages
Global
From €4106EUR$4,500USD£3,489GBP
- Drug Pipelines
- March 2024
- 210 Pages
Global
From €7254EUR$7,950USD£6,164GBP
- Report
- January 2025
- 77 Pages
Global
From €3500EUR$4,109USD£3,078GBP
- Report
- August 2022
- 70 Pages
Global
From €3194EUR$3,500USD£2,714GBP
- Report
- May 2025
- 50 Pages
Global
From €2418EUR$2,650USD£2,055GBP
Bexarotene is an oncology drug used to treat certain types of cancer, including cutaneous T-cell lymphoma (CTCL). It is a retinoid, a type of vitamin A derivative, and works by targeting and killing cancer cells. Bexarotene is available in both oral and topical forms, and is typically used in combination with other treatments. It is generally well-tolerated, with the most common side effects being skin irritation, nausea, and fatigue.
Bexarotene is approved for use in the United States, Europe, and other countries. It is marketed by several pharmaceutical companies, including Eisai, Sun Pharmaceuticals, and Teva Pharmaceuticals. Other companies involved in the development and manufacture of Bexarotene include Celgene, Merck, and GlaxoSmithKline. Show Less Read more
